Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 18.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,124 shares of the pharmaceutical company’s stock after purchasing an additional 176 shares during the period. Chicago Partners Investment Group LLC’s holdings in Vertex Pharmaceuticals were worth $536,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Activest Wealth Management acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Vertex Pharmaceuticals by 450.0% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 45 shares during the period. Flaharty Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter worth $32,000. American National Bank & Trust raised its holdings in shares of Vertex Pharmaceuticals by 515.4% during the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after purchasing an additional 67 shares during the period. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter worth $46,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Wells Fargo & Company raised shares of Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 target price on the stock in a report on Wednesday, August 6th. JPMorgan Chase & Co. upped their price target on shares of Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 8th. HC Wainwright lowered their price target on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating for the company in a research report on Tuesday, August 5th. Truist Financial set a $490.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $494.38.

Vertex Pharmaceuticals Stock Up 0.0%

Shares of VRTX opened at $426.44 on Thursday. The firm has a 50-day moving average price of $397.74 and a 200 day moving average price of $435.58. The firm has a market capitalization of $109.33 billion, a PE ratio of 30.48 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. The firm had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. Vertex Pharmaceuticals’s revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Transactions at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The stock was purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the transaction, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This represents a 12.50% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.